公司概述
Owlet, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it delivers digital parenting solutions including wearable infant health monitors like the Dream Sock. The company provides a digital parenting platform that offers real-time data and insights to parents across the United States, the United Kingdom, and international markets. This business model targets a niche market requiring advanced connectivity and sensor technology to monitor infant vitals. In terms of scale, the company holds a market capitalization of $145.03M and generates annual revenue of $105.71M, supported by an employee base of 108 individuals. These valuation and revenue figures indicate that Owlet, Inc. maintains a significant market presence within the specialized medical device space, though its market cap relative to revenue suggests a capitalization structure typical for growth-oriented technology companies in the healthcare sector that are currently prioritizing market expansion over immediate profitability.
财务健康
Owlet, Inc. reported a revenue of $105.71M for the trailing twelve months, yet the company recorded a net income of -$41.855M and an EBITDA of -$8.059M. The substantial gap between the reported revenue and the significant net loss reveals a cost structure characterized by high operating expenses, likely driven by research and development, sales and marketing, or administrative costs that exceed gross profitability. This financial dynamic indicates that while the company successfully generates top-line sales, its bottom-line economics are currently challenged by operational inefficiencies or high burn rates. The company's free cash flow stands at -$12.104375M, which implies a lack of immediate financial flexibility to fund operations without external capital injections or debt financing. Analyzing the three key margins shows a gross margin of 50.6%, an operating margin of -18.4%, and a profit margin of -37.5%. The healthy gross margin suggests strong pricing power or efficient production of medical devices, whereas the negative operating and profit margins highlight that overhead costs are consuming the majority of the gross profit. The balance sheet displays a cash position of $35.46M against total debt of $13.12M, resulting in a debt-to-equity ratio of 42.26. Despite the negative earnings, the cash balance exceeds debt obligations, suggesting a balance sheet that is not leveraged to dangerous levels, although the negative equity implied by the high debt-to-equity ratio complicates the interpretation of leverage. The current ratio is 1.85, which indicates that the company possesses sufficient short-term liquid assets to cover its short-term liabilities, providing a moderate buffer against liquidity shocks. The return on equity is -802.5% and the return on assets is -7.6%, metrics that reveal management is currently unable to generate positive returns on the capital invested, reflecting the company's early-stage growth challenges or significant restructuring costs.
估值评估
The trailing twelve-month P/E ratio is N/A due to the lack of net income, while the forward P/E is 51.50. The absence of a trailing P/E combined with a forward P/E of 51.50 implies that the market is pricing in expected future earnings growth, assuming profitability will be achieved in the coming periods. The price-to-book ratio stands at 7.28, indicating a substantial market premium over the company's book value, which often signals high investor expectations for future growth or intangible asset value. Alternative valuation metrics such as the price-to-sales ratio of 1.37 and an EV/EBITDA of -16.71 suggest that investors are valuing the company based on revenue generation rather than current profitability. The stock has traded between a 52-week high of $16.94 and a 52-week low of $3.08. Without a specific current price provided in the available facts to calculate a precise percentage, the trading range demonstrates significant volatility, with the asset capable of moving nearly fivefold within a single year. The beta value is 1.98, which indicates that the stock price is nearly twice as volatile as the broader market, making it suitable for risk-tolerant portfolios seeking high beta exposure.
Growth & Income
Owlet, Inc. achieved a revenue growth rate of 29.6% year-over-year, while earnings growth is listed as N/A. The disparity between robust revenue expansion and the inability to report earnings growth implies that top-line sales are outpacing the company's ability to achieve profitability, a common trait in capital-intensive medical device startups. As the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively. This non-dividend status means the company retains all earnings to reinvest into research, development, and market expansion rather than distributing cash to shareholders. The overall growth and income profile is characterized by strong top-line momentum driven by digital parenting solution adoption, coupled with a reinvestment strategy that defers income generation to fund future operational scaling.